The Diabetes Masterclass series stands as a crowning achievement of Dr. Abidi Pharmaceuticals in advancing diabetes management nationwide. Designed exclusively for relevant medical specialists, these scientific-educational symposiums aim to deliver the latest, evidence-based updates on diabetes care and novel therapeutic interventions.

To date, approximately 17,000 physicians have participated in these elite educational sessions. The core curriculum of these masterclasses includes evaluating updated global clinical standards (guidelines) for screening and glycemic control, analyzing the clinical efficacy of novel oral anti-diabetic agents, and conducting real-world case studies to optimize personalized treatment algorithms. Continuous exposure to these updates significantly enhances physicians’ capabilities in diagnosing, managing diabetes, and controlling its associated comorbidities.

Celebrating a Decade of Excellence: The 100th Masterclass

During the commemorative ceremony for the 100th Diabetes Masterclass, Dr. Abidi Pharmaceuticals showcased its decade-long achievements in elevating clinical outcomes for diabetic patients. Attended by prominent physicians, endocrinologists, and university professors, the event provided a platform to review therapeutic milestones and honor the top-tier endocrinology and metabolism experts who have collaborated on this ten-year journey.

Mr. Nima Bararjanian, CEO of Cobel Group, inaugurated the event by emphasizing the company’s vision to serve as a hub for cutting-edge therapeutic solutions. “Over the past ten years, all production lines at Dr. Abidi Pharmaceuticals have been comprehensively upgraded. Today, all 17 primary manufacturing lines are equipped with the most advanced, state-of-the-art global technologies,” he stated.

Expressing gratitude for the enduring trust of the medical community and the public, he added, “We have even more ambitious plans ahead. Through continuous innovation, we strive to profoundly impact public health and improve the quality of life for our compatriots.”

 The Epidemiological Landscape of Diabetes: Global and National Perspectives

According to data from the International Diabetes Federation (IDF), approximately 382 million individuals were living with diabetes globally in 2013, with projections estimating a surge to 592 million by 2035.

Nationally, published reports indicate that in 1403 (Iranian calendar year), the number of diabetic patients in Iran reached an alarming 7,500,000. This exponential growth poses severe clinical and economic challenges to the healthcare system, underscoring the urgent need for strategic planning and the deployment of novel therapeutic solutions.

 A Decade of Clinical Advancements in Iran’s Diabetes Care

Over the past ten years, Iran has witnessed remarkable clinical advancements in diabetes management. The national diagnosis rate has improved to approximately 80%, while the treatment coverage rate has reached 75%. During this decade, innovative classes of pharmacological agents have been introduced to the market. Crucially, these novel therapies not only ensure optimal glycemic control but also offer significant cardioprotective and renoprotective benefits (protecting the heart and kidneys), all while maintaining a highly favorable side-effect profile for patients.

Prominent Key Opinion Leaders (KOLs) shared their insights during the 100th Masterclass:

Dr. Saeed Kalbasi, Subspecialist in Endocrinology and Metabolism: “Through its continuous innovations over the past decade, Dr. Abidi Pharmaceuticals has revolutionized diabetes treatment in the country. Together with the medical and academic communities, we have successfully transformed diabetes management protocols in Iran.”

Dr. Hamidreza Aghaei, Subspecialist in Endocrinology and Metabolism: “The introduction of novel therapeutic regimens by Dr. Abidi Pharmaceuticals has profoundly impacted the trajectory of diabetes care nationwide.”

Dr. Adel Jahed, Subspecialist in Endocrinology and Metabolism, envisioned the future of diabetes care at the intersection of modern technology and pharmacotherapy: “The future of diabetes treatment is like an iceberg; we are currently only seeing the tip. We have a long way to go to reach the optimal therapeutic landscape. Digital health technologies will play a foundational role in this journey, and Dr. Abidi Pharmaceuticals is perfectly positioned to pioneer this transformation.”

Dr. Mojtaba Malek, Subspecialist in Adult Endocrinology and Metabolism and Full Professor at Iran University of Medical Sciences: “The pharmacological solutions provided by Dr. Abidi Pharmaceuticals have empowered physicians with the critical tools necessary to deliver far more effective treatments.”

The successful execution of 100 Diabetes Masterclasses stands as a powerful testament to Dr. Abidi Pharmaceuticals’ unwavering commitment to clinical innovation and enhancing the quality of life for diabetic patients. Moving forward, the company remains dedicated to its mission, painting a brighter, healthier future for diabetes management in Iran.